http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5680461-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-663 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 |
| filingDate | 2006-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7a36077382c1a16019d75551860481a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a000cfaba41aedb992c4cb16fc7577e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42808b9c4c7df63a2e6d6b2d6a5e9a11 |
| publicationDate | 2006-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-5680461-A2 |
| titleOfInvention | PHARMACEUTICAL PRODUCTS THAT INCLUDE BISPHOSPHONATES |
| abstract | 1. A pharmaceutical product in the form of a ready-to-use solution, which comprises a package containing a bisphosphonate solution, where at least the inner surface of the package comprises a plastic material, and where the package is sterilizable by heat. 2. A product according to claim 1, in a unit dose form having a volume of about 20 milliliters to about 500 milliliters. 3. A product according to claim 1, which comprises a pH regulating agent, preferably a basic regulating agent, more preferably an organic based regulating agent. 4. A product according to claim 3, adjusted with an organic base to a physiologically acceptable pH value of pH 5.5 to 8.0 , preferably pH 6.0 to 7.5, more preferably pH 6.5.5.- A product according to claim 4, wherein the organic base is sodium citrate. 6. A product according to claim 4, wherein the organic base is sodium acetate. 7. A product according to claim 4, wherein the base is sodium or potassium phosphate. 8. A product according to claim 4, wherein the base is sodium or potassium hydroxide.12.- A pharmaceutical product, which comprises a package containing a bisphosphonate solution in the form of a ready-to-use solution, comprising: a) a unit dose of bisphosphonate ; b) an organic-based regulatory agent, and a non-ionic isotonic agent, wherein at least the inner surface of the package comprises a plastic material, and where the filled container can be heat sterilized terminally. |
| priorityDate | 2003-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.